Abstract:
The aim of this proposal is to study and exploit the non-classical cross-linkages present in the peptidoglycan layer of bacteria. This layer is vital to the survival of bacilli and is maintained by linking peptide and glycan chains. One the most successful class of antibiotics in human clinical use, namely the ?-lactams and cephalosporins, targets the classical 4?3 linkages. The existing paradigm describes the peptidoglycan layer as a structure largely maintained by classical 4?3 linkages. Our recent studies of one of the most significant human pathogens, Mycobacterium tuberculosis (Mtb), has revealed that its peptidoglycan layer is composed of 3?3 (non-classical cross-links) and undergoes remodeling when the bacterium transitions from one growth phase to another. Other laboratories have recently identified this enzyme in bacteria such as E. coli and B. subtilis suggesting that this enzyme is widely present and vital for viability of bacteria. Emerging evidence from recent publications link remodeling of the peptidoglycan to contain 3?3 transpeptide bonds to adaptation during chronic phase of infection. In a short period of 2 years we have characterized a 3?3 transpeptidase and have now solved the molecular structure of the crystal containing native substrate. This proposal aims to develop and identify small molecules that mimic the substrate inhibit this novel transpeptidase activity. The inhibitor would be a promising new class of antibacterial drug

Public Health Relevance

This proposal aims to investigate novel structures and molecules that are present in all important human bacterial pathogens. It is expected that findings from the proposed studies will lead to development of new interventions to kill bacteria. These drugs/anti-bacterials may be effective against a wide range of bacteria including those that are resistant to existing drugs.

Agency
National Institute of Health (NIH)
Institute
Office of The Director, National Institutes of Health (OD)
Type
NIH Director’s New Innovator Awards (DP2)
Project #
3DP2OD008459-01S1
Application #
8668380
Study Section
Program Officer
Basavappa, Ravi
Project Start
2011-09-30
Project End
2016-06-30
Budget Start
2011-09-30
Budget End
2016-06-30
Support Year
1
Fiscal Year
2013
Total Cost
$200,000
Indirect Cost
$15,500
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Silva, José Rogério A; Bishai, William R; Govender, Thavendran et al. (2016) Targeting the cell wall of Mycobacterium tuberculosis: a molecular modeling investigation of the interaction of imipenem and meropenem with L,D-transpeptidase 2. J Biomol Struct Dyn 34:304-17
Kaushik, Amit; Heuer, Abigail M; Bell, Drew T et al. (2016) An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria. Bioorg Med Chem Lett 26:3572-6
Pelly, Shaaretha; Winglee, Kathryn; Xia, Fangfang et al. (2016) REMap: Operon map of M. tuberculosis based on RNA sequence data. Tuberculosis (Edinb) 99:70-80
Perryman, Alexander L; Yu, Weixuan; Wang, Xin et al. (2015) A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA. J Chem Inf Model 55:645-59
Moraes, Gleiciane Leal; Gomes, Guelber Cardoso; Monteiro de Sousa, Paulo Robson et al. (2015) Structural and functional features of enzymes of Mycobacterium tuberculosis peptidoglycan biosynthesis as targets for drug development. Tuberculosis (Edinb) 95:95-111
Brammer Basta, Leighanne A; Ghosh, Anita; Pan, Ying et al. (2015) Loss of a Functionally and Structurally Distinct ld-Transpeptidase, LdtMt5, Compromises Cell Wall Integrity in Mycobacterium tuberculosis. J Biol Chem 290:25670-85
Kaushik, Amit; Makkar, Nayani; Pandey, Pooja et al. (2015) Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus. Antimicrob Agents Chemother 59:6561-7
Schoonmaker, Maia K; Bishai, William R; Lamichhane, Gyanu (2014) Nonclassical transpeptidases of Mycobacterium tuberculosis alter cell size, morphology, the cytosolic matrix, protein localization, virulence, and resistance to β-lactams. J Bacteriol 196:1394-402
Erdemli, Sabri B; Gupta, Radhika; Bishai, William R et al. (2012) Targeting the cell wall of Mycobacterium tuberculosis: structure and mechanism of L,D-transpeptidase 2. Structure 20:2103-15
Pelly, Shaaretha; Bishai, William R; Lamichhane, Gyanu (2012) A screen for non-coding RNA in Mycobacterium tuberculosis reveals a cAMP-responsive RNA that is expressed during infection. Gene 500:85-92